Key U.S. patent now protects exclusivity for developing stenoparib with the stenoparib-DRP® until April 2042TARPON SPRINGS, Fla., June ...
In an era where cybersecurity is more critical than ever, DRP has become a vital technology for organizations aiming to protect their digital assets, prevent cyber threats, and manage online risks.
TARPON SPRINGS, Fla., April 27, 2026 – Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib ...
Vanta reports that developing a disaster recovery plan is crucial for organizations to minimize downtime and recover swiftly from disruptions.
Phase 1b dose escalation study to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of GS-3583, a FLT3 agonist Fc fusion protein, in patients with advanced solid tumors.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results